EcoDrugPlus

60s Ribosomal Protein L39-Like

Ensembl ID : ENSPPAG00000004891
Gene Symbol: LOC106634287
2 Cross references
29 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L4-Like

Ensembl ID : ENSPPAG00000035309
Gene Symbol: LOC100986141
3 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L4-Like

Ensembl ID : ENSPPAG00000031324
Gene Symbol: LOC100986141
1 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L6

Ensembl ID : ENSPPAG00000009520
Gene Symbol: LOC100976413
2 Cross references
387 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L6-Like

Ensembl ID : ENSPPAG00000022273
Gene Symbol: LOC100995196
1 Cross references
387 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L6-Like

Ensembl ID : ENSPPAG00000028967
Gene Symbol: LOC100973658
2 Cross references
386 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L7a-Like

Ensembl ID : ENSPPAG00000040924
Gene Symbol: LOC100987329
1 Cross references
167 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPPAG00000015632
Gene Symbol: ARAF
4 Cross references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPPAG00000036322
Gene Symbol: ABL1
4 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adam Metallopeptidase Domain 17

Ensembl ID : ENSPPAG00000038185
Gene Symbol: ADAM17
4 Cross references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSPPAG00000037965
Gene Symbol: ADAMTS5
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSPPAG00000025509
Gene Symbol: ADRM1
4 Cross references
255 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).